AU2003221878A1 - G-protein coupled receptor ligands and methods - Google Patents

G-protein coupled receptor ligands and methods

Info

Publication number
AU2003221878A1
AU2003221878A1 AU2003221878A AU2003221878A AU2003221878A1 AU 2003221878 A1 AU2003221878 A1 AU 2003221878A1 AU 2003221878 A AU2003221878 A AU 2003221878A AU 2003221878 A AU2003221878 A AU 2003221878A AU 2003221878 A1 AU2003221878 A1 AU 2003221878A1
Authority
AU
Australia
Prior art keywords
methods
protein coupled
coupled receptor
receptor ligands
relates
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003221878A
Other languages
English (en)
Other versions
AU2003221878A8 (en
Inventor
Ying Jiang
Lin Luo
Nicholas J. Murgolo
Jason S. Simon
Fang Liang Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of AU2003221878A1 publication Critical patent/AU2003221878A1/en
Publication of AU2003221878A8 publication Critical patent/AU2003221878A8/xx
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C07K14/723—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH receptor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G01N2333/726—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Biotechnology (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Neurology (AREA)
  • General Physics & Mathematics (AREA)
AU2003221878A 2002-04-12 2003-04-10 G-protein coupled receptor ligands and methods Abandoned AU2003221878A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US37264002P 2002-04-12 2002-04-12
US60/372,640 2002-04-12
PCT/US2003/011159 WO2003087134A2 (en) 2002-04-12 2003-04-10 G-protein coupled receptor ligands and methods

Publications (2)

Publication Number Publication Date
AU2003221878A1 true AU2003221878A1 (en) 2003-10-27
AU2003221878A8 AU2003221878A8 (en) 2003-10-27

Family

ID=29250884

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003221878A Abandoned AU2003221878A1 (en) 2002-04-12 2003-04-10 G-protein coupled receptor ligands and methods

Country Status (9)

Country Link
US (3) US7338772B2 (enExample)
EP (1) EP1532446B1 (enExample)
JP (4) JP4594623B2 (enExample)
CN (1) CN1324047C (enExample)
AT (1) ATE545866T1 (enExample)
AU (1) AU2003221878A1 (enExample)
CA (1) CA2481508A1 (enExample)
MX (1) MXPA04009959A (enExample)
WO (1) WO2003087134A2 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4594623B2 (ja) * 2002-04-12 2010-12-08 シェーリング コーポレイション Ｇタンパク質共役レセプターリガンドおよび方法
WO2006039256A1 (en) * 2004-09-29 2006-04-13 Glaxo Group Limited Use of gpr103 agonists for modulating feeding behaviour
WO2009043524A2 (en) * 2007-09-11 2009-04-09 Mondobiotech Laboratories Ag Use of a peptide as therapeutic agent
JP5313068B2 (ja) * 2009-03-09 2013-10-09 富士フイルム株式会社 側視内視鏡装置
CA2963579C (en) * 2014-10-14 2023-10-31 Universite De Montreal Biosensor based on g-beta-gamma-interacting proteins to monitor g-protein activation
JP6405352B2 (ja) * 2016-09-16 2018-10-17 株式会社Ｓｕｂａｒｕ 直噴内燃機関のピストン

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4952496A (en) 1984-03-30 1990-08-28 Associated Universities, Inc. Cloning and expression of the gene for bacteriophage T7 RNA polymerase
US5693489A (en) 1984-03-30 1997-12-02 Associated Universities, Inc. Cloning and expression of the gene for bacteriophage T7 RNA polymerase
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US5011912A (en) * 1986-12-19 1991-04-30 Immunex Corporation Hybridoma and monoclonal antibody for use in an immunoaffinity purification system
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
CN1167490A (zh) * 1994-11-10 1997-12-10 人体基因组科学有限公司 人司登尼亚钙蛋白-α
WO1997037967A1 (en) 1996-04-09 1997-10-16 Nps Pharmaceuticals, Inc. Calcilytic compounds
SE9704836D0 (sv) 1997-12-22 1997-12-22 Astra Pharma Inc Novel receptor
WO2000011015A1 (en) 1998-08-24 2000-03-02 Alphagene, Inc. Secreted proteins and polynucleotides encoding them
KR20010080882A (ko) 1998-10-13 2001-08-25 리처드 피. 버군 쥬니어 구성적으로 활성화된 비내생성 인간 ｇ 단백질 결합형수용체
PT1133559E (pt) 1998-11-20 2005-10-31 Arena Pharm Inc Receptor acoplato a proteina g orfao humano, rup3
WO2000031256A1 (fr) 1998-11-20 2000-06-02 Chugai Research Institute For Molecular Medicine, Inc. Nouveau gene codant une proteine membranaire specifique au cerveau
CN1550235A (zh) 1999-04-29 2004-12-01 ŵ��Ų�ڿ˹�˾ 结合肝素的拮抗剂在缓激肽释放的抑制中的应用
EP1189944A4 (en) 1999-06-21 2002-09-11 Smithkline Beecham Corp AXOR16, R CEPTEUR COUPL UNE PROT INE G
CA2311201A1 (en) * 1999-08-05 2001-02-05 Genset S.A. Ests and encoded human proteins
WO2001016316A1 (fr) 1999-08-27 2001-03-08 Takeda Chemical Industries, Ltd. Proteine recepteur couplee a une proteine g et adn correspondant
AU7645700A (en) * 1999-10-07 2001-05-10 Maxygen Aps Single-chain antagonist polypeptides
WO2001048189A1 (fr) 1999-12-28 2001-07-05 Helix Research Institute Nouveaux recepteurs couples a une proteine de liaison au guanosine triphosphate, genes de ces derniers, et production et utilisation de ces derniers
AU2001271838A1 (en) * 2000-07-06 2002-01-21 Bayer Corporation Human neuropeptide y-like g protein-coupled receptor
WO2003020932A1 (en) * 2001-09-03 2003-03-13 Takeda Chemical Industries, Ltd. Novel secretory proteins and dna thereof
JP4594623B2 (ja) * 2002-04-12 2010-12-08 シェーリング コーポレイション Ｇタンパク質共役レセプターリガンドおよび方法

Also Published As

Publication number Publication date
CN1324047C (zh) 2007-07-04
CA2481508A1 (en) 2003-10-23
EP1532446A4 (en) 2006-06-07
JP4594623B2 (ja) 2010-12-08
JP2010279373A (ja) 2010-12-16
US20030223992A1 (en) 2003-12-04
US7338772B2 (en) 2008-03-04
JP2010252805A (ja) 2010-11-11
WO2003087134A3 (en) 2005-03-24
AU2003221878A8 (en) 2003-10-27
JP2006254916A (ja) 2006-09-28
ATE545866T1 (de) 2012-03-15
US8133980B2 (en) 2012-03-13
JP2005528894A (ja) 2005-09-29
JP5284313B2 (ja) 2013-09-11
US7807390B2 (en) 2010-10-05
US20080138348A1 (en) 2008-06-12
MXPA04009959A (es) 2004-12-13
WO2003087134A2 (en) 2003-10-23
EP1532446B1 (en) 2012-02-15
EP1532446A2 (en) 2005-05-25
CN1659438A (zh) 2005-08-24
US20110020354A1 (en) 2011-01-27

Similar Documents

Publication Publication Date Title
AU2002345500A1 (en) Sams modifiers of the p53 pathway and methods of use
WO2003083047A3 (en) MP53s AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE
WO2002099075A3 (en) Prmts as modifiers of the p53 pathway and methods of use
AU2003221878A1 (en) G-protein coupled receptor ligands and methods
WO2002055664A3 (en) Modulating insulin receptor signaling
AU2003211040A1 (en) The eaat2 promoter and uses thereof
WO2002099043A3 (en) P5CRS AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE
WO2004067725A3 (en) Methods of identifying modulators of nmur2-mediated activity
EP1438432A4 (en) LRRCAPS AS MODULATORS OF THE P53 PATH AND METHOD OF USE
WO2003054159A3 (en) Modulating insulin receptor signaling through targeting facl
WO2003073063A3 (en) Modulating insulin receptor signaling through targeting helic1
WO2003066813A3 (en) MINRs AS MODIFIERS OF INSULIN RECEPTOR SIGNALING AND METHODS OF USE
WO2004015069A3 (en) MP2153S AS MODIFIERS OF THE p21 OR p53 PATHWAY AND METHODS OF USE
EP1860199A3 (en) Modulating insulin receptor signaling
WO2003052066A3 (en) Klcs as modifiers of the p53 pathway and methods of use

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase